Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

被引:139
作者
Holm, Karolina [2 ]
Grabau, Dorthe [3 ]
Lovgren, Kristina [2 ]
Aradottir, Steina [2 ]
Gruvberger-Saal, Sofia [2 ]
Howlin, Jillian [2 ]
Saal, Lao H. [2 ]
Ethier, Stephen P. [4 ]
Bendahl, Par-Ola [2 ]
Stal, Olle [5 ]
Malmstrom, Per [2 ]
Ferno, Marten [2 ]
Ryden, Lisa [6 ]
Hegardt, Cecilia [2 ]
Borg, Ake [2 ]
Ringner, Markus [1 ,2 ]
机构
[1] Lund Univ, Dept Oncol, CREATE Hlth Strateg Ctr Translat Canc Res, SE-22184 Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden
[3] Skane Univ Hosp, Dept Clin Pathol, Lab Med, SE-22185 Lund, Sweden
[4] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[5] Linkoping Univ, Div Oncol, Dept Clin & Expt Med, Fac Hlth Sci, SE-58185 Linkoping, Sweden
[6] Lund Univ, Skane Univ Hosp, Dept Surg, SE-22185 Lund, Sweden
基金
瑞典研究理事会;
关键词
Breast cancer; Epigenetics; EZH2; H3K27me3; Molecular subtypes; Polycomb; GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE EZH2; COPY NUMBER ALTERATIONS; GENE-EXPRESSION; ADJUVANT TAMOXIFEN; DNA METHYLATION; PREMENOPAUSAL PATIENTS; MOLECULAR PORTRAITS; CELL-PROLIFERATION; SOMATIC MUTATIONS;
D O I
10.1016/j.molonc.2012.06.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycomb repressive complex 2 (PRC2) and its core member enhancer of zeste homolog 2 (EZH2) mediate the epigenetic gene silencing mark: trimethylation of lysine 27 on histone 3 (H3K27me3). H3K27me3 is characteristic of the chromatin at genes involved in developmental regulation in undifferentiated cells. Overexpression of EZH2 has been found in several cancer types such as breast, prostate, melanoma and bladder cancer. Moreover, overexpression is associated with highly proliferative and aggressive types of breast and prostate tumors. We have analyzed the abundance of EZH2 and H3K27me3 using immunohistochemistry in two large and Well-characterized breast tumor data sets encompassing more than 400 tumors. The results have been analyzed in relation to the molecular subtypes of breast tumors (basal-like, luminal A, luminal B, HER2-enriched and normal-like), as well as in subtypes defined by clinical markers (triple negative, ER+/HER2-/Ki67low, ER+/HER2-/Ki67high and HER2+), and were validated in representative breast cancer cell lines by western blot. We found significantly different expression of both EZH2 and H3K27me3 across all subtypes with high abundance of EZH2 in basal-like, triple negative and HER2-enriched tumors, and high H3K27me3 in luminal A, HER2-enriched and normal-like tumors. Intriguingly, the two markers show an inverse correlation, particularly for the basal-like and triple negative tumors. Consequently, high expression of EZH2 was associated with poor distant disease-free survival whereas high expression of H3K27me3 was associated with better survival. Additionally, none of 182 breast tumors was found to carry a previously described EZH2 mutation affecting Tyr641. Our observation that increased expression of EZH2 does not necessarily correlate with increased abundance of H3K27me3 supports the idea that EZH2 can have effects beyond epigenetic silencing of target genes in breast cancer. (c) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:494 / 506
页数:13
相关论文
共 70 条
[1]   EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast [J].
Bachmann, IM ;
Halvorsen, OJ ;
Collett, K ;
Stefansson, IM ;
Straume, O ;
Haukaas, SA ;
Salvesen, HB ;
Otte, AP ;
Akslen, LA .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :268-273
[2]   DNA methylation epigenotypes in breast cancer molecular subtypes [J].
Bediaga, Naiara G. ;
Acha-Sagredo, Amelia ;
Guerra, Isabel ;
Viguri, Amparo ;
Albaina, Carmen ;
Ruiz Diaz, Irune ;
Rezola, Ricardo ;
Jesus Alberdi, Maria ;
Dopazo, Joaquin ;
Montaner, David ;
de Renobales, Mertxe ;
Fernandez, Agustin F. ;
Field, John K. ;
Fraga, Mario F. ;
Liloglou, Triantafillos ;
de Pancorbo, Marian M. .
BREAST CANCER RESEARCH, 2010, 12 (05)
[3]   EZH2 Y641 mutations in follicular lymphoma [J].
Boedoer, C. ;
O'Riain, C. ;
Wrench, D. ;
Matthews, J. ;
Iyengar, S. ;
Tayyib, H. ;
Calaminici, M. ;
Clear, A. ;
Iqbal, S. ;
Quentmeier, H. ;
Drexler, H. G. ;
Montoto, S. ;
Lister, A. T. ;
Gribben, J. G. ;
Matolcsy, A. ;
Fitzgibbon, J. .
LEUKEMIA, 2011, 25 (04) :726-729
[4]   Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions [J].
Bracken, AP ;
Dietrich, N ;
Pasini, D ;
Hansen, KH ;
Helin, K .
GENES & DEVELOPMENT, 2006, 20 (09) :1123-1136
[5]   EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer [J].
Adrian P. Bracken ;
Diego Pasini ;
Maria Capra ;
Elena Prosperini ;
Elena Colli ;
Kristian Helin .
The EMBO Journal, 2003, 22 (20) :5323-5335
[6]   High Expression of H3K27me3 in Human Hepatocellular Carcinomas Correlates Closely with Vascular Invasion and Predicts Worse Prognosis in Patients [J].
Cai, Mu-Yan ;
Hou, Jing-Hui ;
Rao, Hui-Lan ;
Luo, Rong-Zhen ;
Li, Mei ;
Pei, Xiao-Qing ;
Lin, Marie C. ;
Guan, Xin-Yuan ;
Kung, Hsiang-Fu ;
Zeng, Yi-Xin ;
Xie, Dan .
MOLECULAR MEDICINE, 2011, 17 (1-2) :12-20
[7]   EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling [J].
Chang, Chun-Ju ;
Yang, Jer-Yen ;
Xia, Weiya ;
Chen, Chun-Te ;
Xie, Xiaoming ;
Chao, Chi-Hong ;
Woodward, Wendy A. ;
Hsu, Jung-Mao ;
Hortobagyi, Gabriel N. ;
Hung, Mien-Chie .
CANCER CELL, 2011, 19 (01) :86-100
[8]   Gene expression profiling of breast cell lines identifies potential new basal markers [J].
Charafe-Jauffret, E ;
Ginestier, C ;
Monville, F ;
Finetti, P ;
Adélaïde, J ;
Cervera, N ;
Fekairi, S ;
Xerri, L ;
Jacquemier, J ;
Birnbaum, D ;
Bertucci, F .
ONCOGENE, 2006, 25 (15) :2273-2284
[9]   Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].
Cheang, Maggie C. U. ;
Chia, Stephen K. ;
Voduc, David ;
Gao, Dongxia ;
Leung, Samuel ;
Snider, Jacqueline ;
Watson, Mark ;
Davies, Sherri ;
Bernard, Philip S. ;
Parker, Joel S. ;
Perou, Charles M. ;
Ellis, Matthew J. ;
Nielsen, Torsten O. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750
[10]   Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer [J].
Collett, K ;
Eide, GE ;
Arnes, J ;
Stefansson, IM ;
Eide, J ;
Braaten, A ;
Aas, T ;
Otte, AP ;
Akslen, LA .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1168-1174